UCLouvain

Running trials

• Not yet recruiting

  The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment

  NCT07788573· Université Catholique de Louvain· Source

• Recruiting

  CKD Cachexia and Gut Microbiome

  NCT06986265· Université Catholique de Louvain· Source

• Not yet recruiting

  Effects of HABIT-ILE in Adults with Bilateral Cerebral Palsy

  NCT06767930· Université Catholique de Louvain· Source

• Active, not recruiting

  A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

  NCT06356311· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  CAP48 - Autism in Children and Adolescents

  NCT06149468· Université Catholique de Louvain· Source

• Recruiting

  Flexible Reaching Control in Parkinson Disease

  NCT05908266· Université Catholique de Louvain· Source

• Recruiting

  Gait Control in Parkinson Disease

  NCT05908279· Université Catholique de Louvain· Source

• Active, not recruiting

  CMR-AI and Outcomes in AS

  NCT06128876· Medical University of Vienna· Source

• Active, not recruiting

  Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

  NCT03924895· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS

  2023-507906-15-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates

  NCT05276037· University of Liege· Source

• Recruiting

  GRAALL2014

  NCT02617004· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults

  NCT07000916· Université Catholique de Louvain· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Autism1 recruiting
• Cerebral palsy1 recruiting
• Chronic kidney disease1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Multiple sclerosis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS

  2024-516711-24-00· Phase 1/2· Everimmune· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Cerebral palsy14 works · 1 trial
• Haemophilia13 works · 0 trials
• Idiopathic pulmonary fibrosis10 works · 0 trials
• Cushing's syndrome5 works · 0 trials
• Polycystic kidney disease5 works · 0 trials